- Home
- Reports
- Pharmaceutical
- Rheumatoid arthritis Market
Global Rheumatoid arthritis market Information, by drug type (Nonsteroidal anti-inflammatory drug type (NSAID), Steroids, Biologic agents) by diagnosis (C-Reactive Protein (CRP) Test, CCP, ESR test) by treatment (Synovectomy, Tendon repair, Joint fusion) - Forecast to 2022
ID: MRFR/Pharma/1127-HCR | February 2021 | Region: Global | 85 pages
Market Synopsis of Rheumatoid Arthritis Market:
Market Scenario:
Globally the market for rheumatoid arthritis is increasing rapidly. The major factor that derives the growth of rheumatoid arthritis is the increasing aging population. Furthermore some evidence suggests that people who smoke are at an increased risk of developing rheumatoid arthritis.
Globally the market for rheumatoid arthritis market is expected to grow at the rate of about XX% CAGR from 2016 to 2022.
Study Objectives of Rheumatoid arthritis Market:
- To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the rheumatoid arthritis market
- To provide insights about factors affecting the market growth
- To analyze the rheumatoid arthritis market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To provide country level analysis of the market for segments by drug type, by diagnosis, by treatment and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global
Key Players for Rheumatoid Arthritis Market:
Some of the key players in this market are: Pfizer Inc (U.S), Eli Lilly and company (U.S), Bristol-Myers Squibb Company (U.S), F. Hoffmann-La Roche Ltd (switzerland), Novartis AG (switzerland), Vertex Pharmaceuticals Incorporated (U.S), Sanofi (France), AstraZeneca (U.K) and many others.
Segments:
Global rheumatoid arthritis market has been segmented on the basis of drug type which comprises of Non-steroidal anti-inflammatory drug type (NSAID), Steroids, and Disease-modifying anti-rheumatic drug type (DMARDs) and Biologic agents. On the basis of treatment include Synovectomy, Tendon repair, Joint fusion and Total joint replacement. Furthermore on the basis of diagnosis includes C - reactive protein (CRP) Test, CCP, ESR (Erythrocyte Sedimentation Rate) Test and Synovial Fluid Analysis.
Regional Analysis of Rheumatoid arthritis Market:
Globally North America is the largest market for rheumatoid arthritis. The North American market for rheumatoid arthritis is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for rheumatoid arthritis which is expected to grow at a CAGR of XX%. Furthermore Asia pacific market is expected to be the fastest growing market for rheumatoid arthritis.
The report for Global Rheumatoid Arthritis Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Intended Audience
- Pharmaceutical companies
- Rheumatoid arthritis treatment centers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Frequently Asked Questions (FAQ) :
global rheumatoid arthritis market is estimated to grow at approximately 4% CAGR during the review period (2017-2022).
Huge investments for the development of products related to rheumatoid arthritis treatment and rise in the global economy that is widening the access to the quality care are the major tailwinds pushing the growth of the global rheumatoid arthritis market.
North America holds the largest share in the global rheumatoid arthritis market, followed by Europe and the Asia Pacific, respectively.
Eli Lilly and company (US), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), AstraZeneca (UK), and Sanofi (France), are some of the major players operating in the rheumatoid arthritis market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global rheumatoid arthritis market adopt to gain a larger competitive advantage.
1. INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2. RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3. MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4. MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS AND TREATMENT MARKET, BY AND RA TREATMENT EFFICIENCY MONITORING TESTS. SEROLOGY TEST SEGMENT IS FURTHER SUB-SEGMENTED INTO..
5.1 SEROLOGY TEST
5.1.2 ERYTHROCYTE SEDIMENTATION RATE (ESR)
5.1.3 RHEUMATOID FACTOR (RF)
5.1.4 ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP)
5.5 ANTINUCLEAR ANTIBODY (ANA)
5.6 URIC ACID TEST
5.7 OTHERS TESTS
5.2 RA TREATMENT EFFICIENCY MONITORING TESTS
5.2.1 SALICYLATE LEVEL COUNT
5.2.2 MUSCLE ENZYME TESTS (CPK, ALDOLASE),
5.2.3 CREATININE TEST
6. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT
6.1 DRUG CLASS
6.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUG TYPE (NSAID)
6.1.2 STEROIDS
6.1.3 BIOLOGICALS
6.1.4 OTHER
6.2 SURGERY
6.2.1 SYNOVECTOMY
6.2.2 TENDON REPAIR
6.2.3 JOINT FUSION
6.3 OTHERS
7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS AND TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1 ORAL
7.2 PARENTERAL
7.3 TOPICAL
8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS AND TREATMENT MARKET, BY END USERS
8.1 HOSPITALS AND CLINICS
8.2 ACADEMICS AND RESEARCH
8.3 OTHERS
9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS AND TREATMENT MARKET, BY REGION
9.1.1 AMERICAS
9.1.1.1 NORTH AMERICA
9.1.1.1.1 US
9.1.1.1.2 CANADA
9.1.1.2 SOUTH AMERICA
9.1.2 EUROPE
9.1.2.1 GERMANY
9.1.2.2 FRANCE
9.1.2.3 UK
9.1.2.4 ITALY
9.1.2.5 SPAIN
9.1.2.6 REST OF EUROPE
9.1.3 ASIA PACIFIC
9.1.3.1 JAPAN
9.1.3.2 CHINA
9.1.3.3 INDIA
9.1.3.4 AUSTRALIA
9.1.3.5 REPUBLIC OF KOREA
9.1.3.6 REST OF ASIA PACIFIC
9.1.4 MIDDLE EAST & AFRICA
9.1.4.1 SAUDI ARABIA
9.1.4.2 UAE
9.1.4.3 EGYPT
9.1.4.4 SOUTH AFRICA
9.1.4.5 REST OF MIDDLE EAST & AFRICA
10. COMPETITIVE LANDSCAPE
10.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
10.1.1 STRATEGIC PARTNERSHIP
10.1.2 MERGER & ACQUISITION
11. COMPANY PROFILE
11.1 PFIZER INC
11.1.1 OVERVIEW
11.1.2 PRODUCT OVERVIEW
11.1.3 FINANCIALS
11.1.4 KEY DEVELOPMENTS
11.2 ELI LILLY AND COMPANY
11.2.1 OVERVIEW
11.2.2 PRODUCT OVERVIEW
11.2.3 FINANCIALS
11.2.4 KEY DEVELOPMENTS
11.3 BRISTOL-MYERS SQUIBB COMPANY
11.3.1 OVERVIEW
11.3.2 PRODUCT OVERVIEW
11.3.3 FINANCIALS
11.3.4 KEY DEVELOPMENT
11.4 F. HOFFMANN-LA ROCHE LTD
11.4.1 OVERVIEW
11.4.2 PRODUCT OVERVIEW
11.4.3 FINANCIALS
11.4.4 KEY DEVELOPMENTS
11.5 NOVARTIS AG
11.5.1 OVERVIEW
11.5.2 PRODUCT OVERVIEW
11.5.3 FINANCIALS
11.5.4 KEY DEVELOPMENTS
11.6 ERTEX PHARMACEUTICALS INCORPORATED
11.6.1 OVERVIEW
11.6.2 PRODUCT OVERVIEW
11.6.3 FINANCIALS
11.6.4 KEY DEVELOPMENTS
11.7 ASTRAZENECA
11.7.1 OVERVIEW
11.7.2 PRODUCT OVERVIEW
11.7.3 FINANCIALS
11.7.4 KEY DEVELOPMENTS
11.8 ABBVIE
11.8.1 OVERVIEW
11.8.2 PRODUCT OVERVIEW
11.8.3 FINANCIALS
11.8.4 KEY DEVELOPMENTS
11.9 AMGEN
11.9.1 OVERVIEW
11.9.2 PRODUCT OVERVIEW
11.9.3 FINANCIALS
11.9.4 KEY DEVELOPMENTS
11.10 ROCHE HOLDING AG
11.10.1 OVERVIEW
11.10.2 PRODUCT OVERVIEW
11.10.3 FINANCIALS
11.10.4 KEY DEVELOPMENTS
11.11 OTHERS
12. CONCLUSION
12.1 KEY FINDINGS
12.1.1 FROM CEO’S VIEWPOINT
12.1.2 UNMET NEEDS OF THE MARKET
12.2 KEY COMPANIES TO WATCH
12.3 PREDICTION OF RHEUMATOID DIAGNOSIS AND TREATMENT INDUSTRY
13. APPENDIX
